• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

PCSK9 antibodies safe and effective in treating dyslipidemia

byNicholas WoolfandSai Folmsbee
April 27, 2015
in Cardiology, Chronic Disease, Endocrinology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. From a systematic review, proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies significantly reduced LDL cholesterol levels and all-cause mortality without an increase in serious adverse events.

2. PCSK9 antibodies were also associated with a decreased risk for myocardial infarction in patients with dyslipidemia.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Dyslipidemia affects millions of Americans and contributes to coronary artery disease. Although statin drugs are the first-line treatment for patients with high cholesterol, they are not without risk of adverse events. Recently, antibodies to the enzyme proprotein convertase subtilisin/kexin type 9 (PCSK9) have been shown to effectively lower LDL cholesterol in some clinical trials. To investigate the overall safety and efficacy, the authors performed a systematic review of these trials of PCSK9 antibodies for the treatment of dyslipidemia. From this, PCSK9 antibodies significantly lowered all-cause mortality compared to control treatment (i.e., either placebo or ezetimibe). There was also a 50% reduction in LDL cholesterol levels in patients taking PCSK9 antibodies as opposed to control. Additionally, the risk of myocardial infarction was significantly lower in patients taking PCSK9 antibodies. There was no significant difference in the incidence of adverse events between the two treatment groups. This study is limited in that it analyzed study-level, rather than patient-level, data, and the follow-up period varied widely among the trials included in the review. Overall, these findings suggest that PCSK9 antibodies are potentially a viable treatment strategy for patients with dyslipidemia.

Click to read the study, published today in the Annals of Internal Medicine

Relevant Reading: Anti-PCSK9 monotherapy for hypercholesterolemia: The MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

In-Depth [systematic review]: The authors searched several online sources for phase 2 or 3 clinical trials comparing PCSK9 antibodies to either placebo or ezetimibe. Twenty-four studies that included a total of 10,159 patients met these criteria and were chosen for the meta-analysis. The findings demonstrated that PCSK9 antibodies significantly reduced all-cause mortality compared to non-PCSK9 treatments (OR, 0.45; p = 0.015); however, there was no significant difference between the groups with respect to cardiovascular mortality (OR 0.50; p = 0.084). There was a significant 47.49% mean difference in reduction of LDL cholesterol for patients taking PCSK9 antibodies as opposed to those who did not (95% CI -69.64% to -25.35%; p < 0.001). Treatment with PCSK9 antibodies also significantly reduced the risk for myocardial infarction, with rates of 0.58% in patients taking PCSK9 and 1.00% in patients who did not (OR 0.49; p = 0.03). There was no significant difference in the incidence of serious adverse events between the two treatment groups, with the rates of adverse events being 9.26% in PCSK9 patients and 7.73% in non-PCSK9 patients (OR 1.01; p = 0.879).

RELATED REPORTS

Protein-truncating variants in apolipoprotein B and PCSK9 genes associated with lower exposure to atherogenic LDL cholesterol and risk of coronary heart disease

No known association between PCSK9 gene variants and risk of heart failure

Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease

Image: CC/Wiki

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cholesterolpcsk9
Previous Post

AAP policy addresses appropriate discharge timing for healthy term newborns

Next Post

2 Minute Medicine Rewind April 19 – April 26, 2015

RelatedReports

PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study
Cardiology

Protein-truncating variants in apolipoprotein B and PCSK9 genes associated with lower exposure to atherogenic LDL cholesterol and risk of coronary heart disease

February 6, 2023
Quick Take: Association of African Ancestry with Electrocardiographic Voltage and Concentric Left Ventricular Hypertrophy: The Dallas Heart Study
Cardiology

No known association between PCSK9 gene variants and risk of heart failure

December 22, 2022
Ivabradine ineffective in stable coronary artery disease [SIGNIFY trial]
Cardiology

Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease

November 22, 2022
Gender conformity influences use of laxatives and muscle-building products
Cardiology

Risk of myopathy and myalgia among statin users may be small and clinically insignificant

September 20, 2022
Next Post
Three ultrasonographic findings portend increased risk of malignancy in thyroid nodules

2 Minute Medicine Rewind April 19 – April 26, 2015

PET scans in early-stage Hodgkin’s lymphoma may help guide therapy [RAPID trial]

Hodgkin’s Lymphoma survivors may have higher cardiovascular disease risk

APOL1 variants linked to increased risk of renal disease among black patients

Maintenance dialysis linked with increased incidence, worse survival of CPR

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Exhaled volatile organic compounds predict bronchopulmonary dysplasia in preterm infants
  • Wellness Check: Mental Health
  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options